Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis

Hepatology Research

Volumn 43, Issue 10, 2013, Pages 1040-1051

  Huang, Rui ^a   Hao, Yingying ^b   Zhang, Jun ^a   Wu, Chao ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Adefovir; Chronic hepatitis B; Combination therapy; Interferon

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA1B INTERFERON; ALPHA2B INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; APATHY; ARTICLE; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; COPY NUMBER VARIATION; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EMBASE; FATIGUE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JADAD SCALE; LEUKOPENIA; MALAISE; MEDLINE; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SEROCONVERSION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 84885033231     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12058     Document Type: Article

References (35)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
3. Lin SM, Yu ML, Lee CM etal. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
5. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
6. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275-284.
7. Janssen HL, van Zonneveld M, Senturk H etal. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
8. Marcellin P, Lau GK, Bonino F etal. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
9. Marcellin P, Avila C, Wursthorn K etal. Telbivudine (LDT) plus peg-interferon (PEGIFN) in HBeAg-positive chronic hepatitis B - very potent antiviral efficacy but risk of peripheral neuropathy (PN). J Hepatol 2010; 52: S6-7.
10. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
11. Li YB. Clinical efficacy of PegIFNα-2a plus adefovir dipivoxil in HBeAg positive chronic hepatitis B treatment. Zhong Hua Lin Chuang Gan Ran Bing Za Zhi (Chin J Infect Dis) 2008; 1: 168-170.
12. Wang YD, Zhao CY, Wang W etal. Improved efficacy by individualized combination therapy with peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology 2012; 59: 680-686.
13. Wu HR. Efficacy of adefovir dipivoxil plus recombinant interferon α-2b for chronic hepatitis B. Zhong Guo Chu Ji Wei Sheng Bao Jian (Chin Primary Health Care) 2012; 2: 96-97.
14. Gao F, Zhao LF. The efficacy of interferon α-2b or adefovir dipivoxil monotherapy and combination therapy in HBeAg positive chronic hepatitis B patients. Zhong Guo Yi Liao Qian Yan (China Healthcare Innovation) 2011; 6: 11, 28.
15. Wu SH. Clinical trial of recombinant human interferon α-2b plus adefovir dipivoxil for chronic hepatitis B. Zhong Guo Yi Xue Chuang Xin (Med Innovation China) 2010; 7: 65-66.
16. Wu FY. Efficacy of interferon-α plus adefovir dipivoxil for hepatitis B e antigen-positive chronic hepatitis B. Jiang Xi Yi Yao (Jiangxi Med J) 2010; 45: 1114-1115.
17. Luo XP, Jing JS, Chen HB etal. Interferon plus adefovir dipivoxil combination therapy in chronic hepatitis B: two years follow-up. Gan Zang (Chin Hepatol) 2010; 3: 233-234.
18. Ding WM. Efficacy of pegylated interferon-(alpha)2a plus adefovir dipivoxil for 22 chronic hepatitis B patients. Zhong Guo Xian Dai Yao Wu Ying Yong (Chin J Modern Drug Application) 2010; 4: 164-165.
19. Ao FJ, Ma WM, Zhou BP etal. Comparison of efficacy and safety of pegylated interferon alfa-2a or adefovir dipivoxil monotherapy with combination therapy in HBeAg positive chronic hepatitis B patients. Chin J Infect Dis 2010; 4: 214-217.
20. Piccolo P, Lenci I, Demelia L etal. A randomized controlled trial of pegylated interferon-(alpha)2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14: 1165-1174.
21. Jing JS, Sun BZ, Zhou H etal. Interferon monotherapy or combined with lamivudine, adefovir, Thymosin-α1 in treating HBeAg positive, genetype C chronic hepatitis B. Gan Zang (Chin Hepatol) 2009; 2: 137-139.
22. Jiang MX, Liu CX, Lv WW. Efficacy of adefovir dipivoxil plus interferon α-1b for chronic hepatitis B. Zhong Guo Yi Yao Dao Bao (China Med Herald) 2009; 6: 38-39.
23. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl 1): S2-19.
24. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49: S122-128.
25. Sarin SK, Kumar M, Hissar S etal. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment. Hepatobiliary Pancreat Dis Int 2006; 5: 374-380.
26. Sarin SK, Sood A, Kumar M etal. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96-104.
27. Economou M, Manolakopoulos S, Trikalinos TA etal. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005; 11: 5882-5887.
28. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009; 18: 1655-1666.
29. Shi Y, Wu YH, Shu ZY etal. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. Hepatobiliary Pancreat Dis Int 2010; 9: 462-472.
30. Wursthorn K, Lutgehetmann M, Dandri M etal. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684.
31. Lutgehetmann M, Volzt T, Quaas A etal. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13: 57-66.
32. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49 (5 Suppl): S122-128.
33. Ingiliz P, Valantin MA, Thibault V etal. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008; 13: 895-900.
34. Erhardt A, Blondin D, Hauck K etal. Response to interferon alpha is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013.
35. Cooksley WG, Piratvisuth T, Lee SD etal. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305.